Ulcerative Colitis, Active Moderate Clinical Trial
Official title:
A Phase 1b Multi-Center, Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Plasma Exposure of TD-1473 in Subjects With Moderately-to-Severely Active Ulcerative Colitis
This study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of TD-1473 in subjects with moderately-to-severely active UC over 28 days. This exploratory study will also serve as a signal seeking endeavor to demonstrate biologic effect associated with TD-1473 through biomarker analysis and clinical, endoscopic, and histologic assessments.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01481142 -
Adacolumn in Refractory UC Patients Trial
|
Phase 4 | |
| Recruiting |
NCT01671956 -
Evaluation of Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of Bertilimumab in Patients With Active Moderate to Severe Ulcerative Colitis
|
Phase 2 | |
| Active, not recruiting |
NCT02390726 -
Fecal Microbiota Transplant in the Treatment of Ulcerative Colitis
|
Early Phase 1 |